Tenaya Therapeutics Inc. (TNYA)
NASDAQ: TNYAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TNYA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $65.32M
- EPS (TTM)
- -$0.48
- Dividend yield
- None
- 52-week range
- 0.28 – 1.46
- Day range
- 0.2827 – 0.3209
- Volume / Avg
- 4.34M / 2.96M
- Beta
- —
- Shares outstanding
- 227.93M
52-week range
TNYA stock today
On Nov 20, TNYA ended the session at $0.2866, shedding $0.0119 (3.99%), versus the S&P 500's 3.70% decline. At this level, TNYA sits near the bottom of its 52-week range of $0.28 to $1.46: 80.4% below the high, set on Dec 10, 2025 and 2.4% above the low. TNYA is down 59.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 76.7%.
Tenaya Therapeutics has posted a net loss over the last twelve months (EPS of -$0.48), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Tenaya Therapeutics
Company profileTenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Faraz Ali M.B.A.
- Headquarters
- South San Francisco, CA
- Employees
- 70
- IPO year
- 2021
- Website
- tenayatherapeutics.com
Financial highlights
Full financialsTenaya Therapeutics reported a net loss of $90.6 million, compared with a loss of $111.1 million a year earlier. Diluted earnings per share came in at -$0.59.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-90.60M | $-111.13M | $-124.08M | $-123.67M | $-72.72M |
| EPS (diluted) | $-0.59 | $-1.31 | $-1.68 | $-2.76 | $-4.10 |
Analyst forecast
ForecastConsensus (6 analysts)
none
Avg. price target
$3.20+1016.54%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.08 vs $-0.10
- Surprise
- +20.00%
Tenaya Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ATRAAtara Biotherapeutics Inc. | 6.33 | -0.16% | $64.49M | vs TNYA |
| CRDFCardiff Oncology Inc. | 0.8528 | -4.46% | $66.34M | vs TNYA |
| NMRANeumora Therapeutics Inc. | 0.3339 | -3.78% | $63.01M | vs TNYA |
| CSBRChampions Oncology Inc. | 4.34 | -1.36% | $60.41M | vs TNYA |
| CHRSCoherus Oncology Inc. | 0.3698 | -4.47% | $57.15M | vs TNYA |
| OKYOOKYO Pharma Limited | 1.07 | -7.76% | $56.15M | vs TNYA |
| CGTXCognition Therapeutics Inc. | 0.5822 | -3.06% | $55.37M | vs TNYA |
| BDTXBlack Diamond Therapeutics Inc. | 1.31 | -5.76% | $75.28M | vs TNYA |
Indexes, lists and sector
Tenaya Therapeutics stock FAQ
What is Tenaya Therapeutics's stock price today?
TNYA last traded at $0.2866 as of Nov 20, 4:00 PM EST, down 3.99% on the day. Prices are delayed at least 15 minutes.
Who is Tenaya Therapeutics's CEO?
Mr. Faraz Ali M.B.A. is the chief executive officer of Tenaya Therapeutics Inc., which has about 70 employees.
What is the TNYA 52-week high?
The 52-week high for TNYA is $1.46 and the 52-week low is $0.28. The stock is currently 80.4% below its high.